68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

This study uses bone marrow biopsy as a gold standard or reference standard to evaluate the diagnostic efficacy (Sensitivity, Specificity, Positive prediction rate, Negative prediction rate) of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.

Inclusion criteria

• Age ≥18 years old;
• Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
• The expected survival time is over 3 months
• Voluntarily sign informed consent.
• Willing and able to follow the research protocol;
• The subject must be able to lie on the scanning bed for 20 minutes;

Exclusion criteria

• Known allergic history to 68Ga FAPI or its excipients;
• Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history);
• Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia;
• pregnant and lactating women;
• Workers who are exposed to radiation for a long period of time;
• Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis;
• Participating in other interventional clinical trials within 1 month before screening;
• Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers;
• There are other circumstances that the researcher thinks are not suitable for participating in this study;